LIMN.US Liminatus Pharma, Inc. Class A Common Stock

Healthcare Biotechnology USA Stocks
2.99 USD
Close of Nov 15, 2026
2.40 141.50
Market cap
USD 4.02M
P/E
-
P/B
13.36x
ROE
-1,683.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is LIMN.US undervalued?

Graham number

The Graham number of Liminatus Pharma, Inc. Class A Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Liminatus Pharma, Inc. Class A Common Stock fundamental analysis

No fundamental analysis for Liminatus Pharma, Inc. Class A Common Stock yet.

Liminatus Pharma, Inc. Class A Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Liminatus Pharma, Inc. Class A Common Stock

Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.

Full company profile